

October 18, 2016



UPDATE -- Tonix Pharmaceuticals to Present at Dawson James Securities 2016 Small Cap Growth Stock Conference

NEW YORK, Oct. 18, 2016 (GLOBE NEWSWIRE) -- [Tonix Pharmaceuticals Holding Corp.](#) (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present at the Second Annual Dawson James Securities Small Cap Growth Stock Conference being held October 20, 2016 in Jupiter, Florida.

Seth Lederman, M.D., president and chief executive officer of Tonix, will provide a corporate update and an overview of Tonix's [PTSD](#) clinical program. Tonix recently announced a successful end-of-phase 2 meeting with the U.S. Food and Drug Administration (FDA), as well as positive data from its randomized, double-blind, placebo-controlled Phase 2 AtEase clinical trial evaluating TNX-102 SL in military-related PTSD. Dr. Lederman's presentation will include planned next steps for this program.

Event: Dawson James Securities 2016 Small Cap Growth Stock Conference
Date: Thursday, October 20, 2016
Time: 4:30 PM (Eastern Time)
Location: Wyndham Grand Jupiter at Harbourside Place, Jupiter, Florida

The presentation will be webcast live and remain available for 90 days following the presentation. To access the webcast, please visit the [Events](#) tab of the [Investor Relations](#) section of Tonix's website at www.tonixpharma.com.

TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an Investigational New Drug and has not been approved for any indication.

About Tonix Pharmaceuticals Holding Corp.

Tonix is developing next-generation medicines for common disorders of the central nervous system, with its lead program focusing on PTSD. This disorder is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect,"

and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission (the “SEC”) on March 3, 2016, and future periodic reports filed with the SEC on or after the date hereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.

Contacts

Bradley J. Saenger, CPA
Chief Financial Officer
investor.relations@tonixpharma.com
(212) 980-9155 x107

Jessica Smiley
Investor Relations
investor.relations@tonixpharma.com
(212) 980-9155 x185

Edison Advisors (investors)
Tirth Patel
tpatel@edisongroup.com
(646) 653-7035

Dian Griesel Int'l (media)
Susan Forman / Laura Radocaj
sforman@dgicomm.com
lradocaj@dgicomm.com
(212) 825-3210



Source: Tonix Pharmaceuticals Holding Corp.